Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery.
about
Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screeningInduced pluripotent stem cells as a disease modeling and drug screening platformA reduction in ATP demand and mitochondrial activity with neural differentiation of human embryonic stem cells.Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytesCombining hypoxia and bioreactor hydrodynamics boosts induced pluripotent stem cell differentiation towards cardiomyocytes.Cardiogenic induction of pluripotent stem cells streamlined through a conserved SDF-1/VEGF/BMP2 integrated networkHuman stem cells for modeling heart disease and for drug discovery.Assessing the translatability of in vivo cardiotoxicity mechanisms to in vitro models using causal reasoning.An early requirement for nkx2.5 ensures the first and second heart field ventricular identity and cardiac function into adulthoodNitric oxide-cyclic GMP signaling in stem cell differentiationEssential and unexpected role of Yin Yang 1 to promote mesodermal cardiac differentiationBiomaterials for pluripotent stem cell engineering: From fate determination to vascularization.SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells.Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies.Guiding differentiation of stem cells in vivo by tetracycline-controlled expression of key transcription factors.Embryonic template-based generation and purification of pluripotent stem cell-derived cardiomyocytes for heart repair.Current status of drug screening and disease modelling in human pluripotent stem cells.Considerations in designing systems for large scale production of human cardiomyocytes from pluripotent stem cells.Targeting cardiac potassium channels for state-of-the-art drug discovery.Determination of the human cardiomyocyte mRNA and miRNA differentiation network by fine-scale profiling.Quantitative Assessment of Sialo-Glycoproteins and N-Glycans during Cardiomyogenic Differentiation of Human Induced Pluripotent Stem Cells.The Future of Cardiovascular Regenerative Medicine.Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.BMP4 promotes EMT and mesodermal commitment in human embryonic stem cells via SLUG and MSX2.Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype.Cardiac differentiation of pluripotent stem cells.Steps toward Maturation of Embryonic Stem Cell-Derived Cardiomyocytes by Defined Physical Signals.Drug discovery models and toxicity testing using embryonic and induced pluripotent stem-cell-derived cardiac and neuronal cellsPharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells.YY1 Expression Is Sufficient for the Maintenance of Cardiac Progenitor Cell State.Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.Shortcuts to making cardiomyocytes.Cell-Surface Marker Signature for Enrichment of Ventricular Cardiomyocytes Derived from Human Embryonic Stem Cells
P2860
Q26799470-D0C07DE1-A907-4ECB-9B75-E3372200153CQ26865689-62CEDED4-D24F-4A1C-8B42-9D35442F3861Q30497916-553165F2-5C4F-4B2F-8DD1-DE0D2298A46AQ30574106-8EC1E311-9CD0-499D-A215-7B53DF88A3D0Q30597186-931F4B02-F16B-480A-80F8-0AED5DB75A5AQ33550799-C4C10DC7-3B39-4D84-8D9D-8314419049D4Q34433363-6E94B960-34C8-4FC7-9053-66073BFBC381Q34980120-631A2E91-4F7C-4704-9C80-E90691F0697AQ35181554-B1C129F1-E8E7-4DD8-B451-785F7669EA69Q35596709-019DCDC5-D3B3-4B29-A555-1A3FAB8402E9Q36777260-8B925F59-3942-4501-AE0C-9A8C53C6DC06Q37103251-ED04A7CD-F6A6-4781-83CA-3434377EE78AQ37104201-0E2B83E2-7596-4032-9DDE-FFBABB289A30Q37573646-257F7EA6-4428-4958-AC10-0A417F6872A8Q37833892-4E1A646D-C39B-4960-B743-E2F1950BEC25Q37960089-12FDB999-9EFA-4D5A-B73E-74843625C733Q37987327-09849A36-9F7D-4A1E-B5B0-A7183586CD5DQ37999164-496C27EF-E1B7-4B7E-9D65-7D15B2D81FBEQ38027106-C4747ABF-BB95-4C31-A788-C90C404F322DQ38034129-E934C287-70C9-40C1-BCCE-ACCA3BE46FA8Q38180213-62F7CA41-E3C9-49AC-A99F-1435A580C502Q38268573-17876570-3ECB-45A2-A7C9-D98E78D850D4Q38500076-8BAD405D-08DC-4965-8B1E-E0BEA86DBD9BQ38683295-BA668231-369B-4C59-9C18-A9D62392FAE4Q38850633-0DAB3974-DA64-4519-89C1-D4B120C22A09Q38874111-78084882-AAFB-4FEA-921C-E376E42C5378Q39022844-47EBB42A-D480-49DA-8913-93977B817AC8Q39129176-C5BD2093-FD21-45FC-819E-1A8A9326E86EQ39747622-C20071B9-C5C5-4860-835B-C719E9254BE5Q41018766-27D73789-50F9-46B9-A94B-4D76676C1003Q42175982-F40E95FA-3D3D-4965-87A9-F07061D1FDD7Q45366611-1FA9D158-2914-42D2-8E3D-D96FE2B3F879Q46692121-E363143E-2FBC-4AA7-8072-479F5F0BA779Q47611653-A294B777-1904-4D17-AB0D-694FD9C3E7D5Q51725761-45314F88-6622-4761-9D08-A198ABC90875Q58772675-2CA932C3-1610-4D64-A88E-65164CA17781
P2860
Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiomyocytes from human plur ...... e medicine and drug discovery.
@en
Cardiomyocytes from human plur ...... e medicine and drug discovery.
@nl
type
label
Cardiomyocytes from human plur ...... e medicine and drug discovery.
@en
Cardiomyocytes from human plur ...... e medicine and drug discovery.
@nl
prefLabel
Cardiomyocytes from human plur ...... e medicine and drug discovery.
@en
Cardiomyocytes from human plur ...... e medicine and drug discovery.
@nl
P1476
Cardiomyocytes from human plur ...... e medicine and drug discovery.
@en
P2093
Robert Passier
Stefan R Braam
P304
P356
10.1016/J.TIPS.2009.07.001
P577
2009-09-15T00:00:00Z